 Around 800,000 Americans suffer from strokes every year; of these, 160,000 are caused by atrial fibrillation (afib). Afib is when the heart doesn’t beat properly, and this affects a pouch on the heart called the left atrial appendage (LAA). When someone has afib, the LAA becomes a breeding ground for clots. These clots can escape the LAA and travel to the brain, causing stroke; consequently, afib patients are five times more likely to have a stroke. Flow MedTech, Inc. has developed patent protected technology to reduce this high risk of stroke for patients suffering from afib. The solution is an implantable balloon that inflates and conforms to an individual’s uniquely shaped LAA, blocking it off from the rest of the heart and preventing clot formations and clots escaping and traveling to the brain, thereby reducing stroke risk.
Flow MedTech’s minimally-invasive catheter precisely delivers what is the first easy-to-use and detachable balloon implant. Flow MedTech’s chosen balloon material has been proven to reduce clots, reduce infection, and is FDA cleared for cardiac implantable use. Flow MedTech started because both of the founders not only had fun but also had a passion for creating something truly new that had the potential to save millions of patients from suffering. As Biomedical Engineers from Georgia Tech, each founder had the technical expertise to create an innovative device to help reduce the high risk of stroke in patients suffering from afib. Flow MedTech, Inc. is a portfolio company of Health Wildcatters accelerator program located in Dallas, TX. For more information, please visit flow-medtech.com. |
AccelNow 